BTA 188

Drug Profile

BTA 188

Latest Information Update: 08 Oct 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biota Holdings
  • Class Antivirals
  • Mechanism of Action Rhinovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rhinovirus infections

Most Recent Events

  • 08 Oct 2003 Discontinued - Preclinical for Rhinovirus infections in Australia (PO)
  • 05 May 2001 A preclinical study has been added to the pharmacokinetics section
  • 03 May 2001 Preclinical development for Rhinovirus infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top